TransformPV goes live at Otsuka Pharmaceutical Development & Commercialization, Inc

December 11, 2016

Vitrana adds another Milestone to its ongoing successful implementation of TransformPV with the global clientele, Otsuka Pharmaceutical Development & Commercialization, Inc. “Goes Live” with TransformPV for meeting FDA eMDR requirement. Otsuka, the leading pharmaceuticals company has implemented Vitrana’s TransformPV solution to meet its R3 eMDR regulatory requirements. TransformPV has enabled Otsuka to:

  • Avoid the double data entry in source system (Argus) and eSubmitter
  • Submit and track eMDR report through source system (Argus)
  • Have single source of truth for data entry and submission tracking
  • Easy to understand R2-HL7 side by side, which takes away the difficulty of understanding HL7 structure for the business users


Vitrana uses cookies to to analyse our traffic and to personalise the content. We also disclose information about your use of our site with our analytics partners. Additional details are available in our cookie policy.

Accept Cookies